Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

ClinicalTrials.gov ID: NCT02333188

Public ClinicalTrials.gov record NCT02333188. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I/II trial studies the side effects of genetic analysis-guided dosing of paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRABRAX) in treating patients with gastrointestinal cancer that has spread to other parts of the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.

Study identification

NCT ID: NCT02333188
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: University of Chicago; Other
Enrollment: 50 participants

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2014
Primary completion: Nov 30, 2017
Completion: Nov 30, 2017
Last update posted: May 30, 2023

2014 – 2017

United States locations

U.S. sites: 8
U.S. states: 4
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60637	—
Decatur Memorial Hospital	Decatur	Illinois	62526	—
NorthShore University Health System	Evanston	Illinois	60201	—
Ingalls Memorial Hospital	Harvey	Illinois	60426	—
Fort Wayne Medical Oncology/Hematology	Fort Wayne	Indiana	46845	—
Indiana University Medical Center	Indianapolis	Indiana	46202	—
The University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	48109	—
Virginia Mason	Seattle	Washington	98101	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02333188, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 30, 2023 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02333188 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →